Free Trial

Beam Therapeutics (BEAM) News Today

Beam Therapeutics logo
$29.02 +1.50 (+5.45%)
(As of 12:57 PM ET)
Beam Therapeutics' (BEAM) "Buy" Rating Reiterated at HC Wainwright
Beam Therapeutics Appoints Sravan Emany as Chief Financial Officer
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 8.6% - Still a Buy?
Beam Therapeutics Inc. stock logo
Charles Schwab Investment Management Inc. Grows Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)
Charles Schwab Investment Management Inc. raised its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 6.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 629,492 shares of the comp
Beam Therapeutics Inc. stock logo
20,800 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Polar Asset Management Partners Inc.
Polar Asset Management Partners Inc. acquired a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 20,800 shares of the company's stock, valued at approximately $510,000. Sever
Beam Therapeutics Names Sravan K. Emany as CFO
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Shares Up 8.6% - Still a Buy?
Beam Therapeutics (NASDAQ:BEAM) Trading Up 8.6% - Here's What Happened
Beam Therapeutics Strengthens Board with Pharma Veteran
Beam Therapeutics Inc. stock logo
Redmile Group LLC Lowers Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)
Redmile Group LLC trimmed its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 5.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,611,013 shares of the company's stock after selling 92,048 sha
Beam Therapeutics Inc. stock logo
Erste Asset Management GmbH Purchases New Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)
Erste Asset Management GmbH acquired a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 21,700 shares of the company's stock, valued at approximately $544,000. Other large i
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Stock Position Reduced by Fmr LLC
Fmr LLC cut its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 4.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,211,517 shares of the company's stock after selling 196,178 shares during the period. Fmr
Beam Therapeutics Inc. stock logo
Walleye Capital LLC Buys 22,664 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
Walleye Capital LLC raised its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 21.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 127,588 shares of the company's stock after buying an addition
Brokerages Set Beam Therapeutics Inc. (NASDAQ:BEAM) PT at $44.91
Beam Therapeutics Inc. stock logo
Intech Investment Management LLC Invests $512,000 in Beam Therapeutics Inc. (NASDAQ:BEAM)
Intech Investment Management LLC purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 20,892 shares of the company's stock, valued
Beam Therapeutics Inc. stock logo
Bellevue Group AG Acquires 100,000 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
Bellevue Group AG raised its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,518,121 shares of the company's stock after purchasing an
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, seven have ass
Beam Therapeutics Inc. stock logo
Algert Global LLC Has $1.07 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)
Algert Global LLC grew its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 282.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,523 shares of the company's stock after purchasing an additional
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Stake Boosted by Quest Partners LLC
Quest Partners LLC grew its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 410.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,193 shares of the company's stock after purchasing an additiona
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 12,310,000 shares, an increase of 10.3% from the October 15th total of 11,160,000 shares. Based on an average daily trading volume, of 890,600 shares, the short-interest ratio is currently 13.8 days.
Beam Therapeutics
Beam Therapeutics management to meet virtually with Cantor Fitzgerald
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Acquired by Sumitomo Mitsui Trust Group Inc.
Sumitomo Mitsui Trust Group Inc. lifted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 59.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,552,829 shares of the company's stock after acqui
Beam Therapeutics Inc. stock logo
Baillie Gifford & Co. Has $8.76 Million Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)
Baillie Gifford & Co. lowered its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 42.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 357,698 shares of the company's stock after selling 265,942 shares during the period. Baillie G
Beam Therapeutics participates in a conference call with JPMorgan
Beam Therapeutics Inc. stock logo
Research Analysts Issue Forecasts for BEAM FY2024 Earnings
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for Beam Therapeutics in a research report issued on Wednesday, November 6th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($4.43) per
Beam Therapeutics Inc. stock logo
Beam Therapeutics Inc. (NASDAQ:BEAM) President Sells $1,347,259.60 in Stock
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) President Giuseppe Ciaramella sold 51,110 shares of Beam Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $26.36, for a total transaction of $1,347,259.60. Following the completion of the transaction, the president now owns 109,150 shares in the company, valued at approximately $2,877,194. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Beam Therapeutics Inc. stock logo
FY2024 EPS Estimate for Beam Therapeutics Lowered by Analyst
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for shares of Beam Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now forecasts tha
Beam Therapeutics Inc. stock logo
ARK Investment Management LLC Sells 1,095,040 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM)
ARK Investment Management LLC cut its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 14.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,531,099 shares of the company's stock after selling
Beam Therapeutics Inc. stock logo
Beam Therapeutics' (BEAM) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Beam Therapeutics in a research report on Thursday.
Beam Therapeutics Inc. stock logo
Wedbush Cuts Earnings Estimates for Beam Therapeutics
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at Wedbush dropped their FY2024 earnings per share (EPS) estimates for shares of Beam Therapeutics in a research report issued on Tuesday, November 5th. Wedbush analyst D. Nierengarten now forecasts that the company w
Beam Therapeutics Inc. stock logo
William Blair Has Negative Estimate for BEAM FY2024 Earnings
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - William Blair reduced their FY2024 earnings per share estimates for shares of Beam Therapeutics in a note issued to investors on Tuesday, November 5th. William Blair analyst S. Corwin now anticipates that the company will earn ($4.56) per share
Beam Therapeutics Inc. stock logo
Beam Therapeutics (NASDAQ:BEAM) Upgraded by Leerink Partnrs to Strong-Buy Rating
Leerink Partnrs raised shares of Beam Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday.
Scotiabank Remains a Hold on Beam Therapeutics (BEAM)
Get Beam Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.

Coins Set to Soar with a Pro-Crypto White House (Ad)

Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…

Click here to reserve your free seat at the Crypto Community Summit

BEAM Media Mentions By Week

BEAM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BEAM
News Sentiment

0.63

0.67

Average
Medical
News Sentiment

BEAM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BEAM Articles
This Week

21

6

BEAM Articles
Average Week

Get Beam Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BEAM) was last updated on 12/10/2024 by MarketBeat.com Staff
From Our Partners